Researchers have developed a composite SASP Score that quantifies the burden of senescent cells in the body by analyzing proteomic data from blood samples. This score is derived from the senescence-associated secretory phenotype (SASP), a distinct profile of pro-inflammatory and pro-growth signals secreted by senescent cells, which accumulate with age and contribute to various chronic conditions. The study utilized a Guided Autoencoder with Transformer (GAET) model, integrating data from the UK Biobank Pharma Proteomics Project, to establish a robust correlation between the SASP Score and mortality risk.

The significance of this work lies in its potential to provide a practical, quantifiable measure of cellular senescence, which is a recognized hallmark of biological aging. The SASP Score not only serves as an indicator of the body-wide burden of senescent cells but also correlates with the onset of serious chronic medical conditions such as dementia, chronic obstructive pulmonary disease (COPD), myocardial infarction, and stroke. Importantly, the study demonstrated that interventions like multimodal exercise could positively influence the SASP Score trajectory over an 18-month period, suggesting that lifestyle modifications may mitigate the effects of senescence.

This advancement has implications for both clinical research and therapeutic development. The ability to measure the SASP Score could shift current paradigms in aging research by providing a quantifiable biomarker for evaluating the efficacy of anti-aging interventions and therapies targeting senescent cells. Furthermore, it may accelerate drug development timelines by offering a clear endpoint for clinical trials aimed at reducing the burden of senescent cells and improving healthspan.

HealthspanWire tracks this as a research signal: Senolytic therapies are showing clinical efficacy in human trials

Source: fightaging.org